Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The San Francisco-based company said it signed a definitive agreement to acquire Singular Bio for $55 million. Singular Bio specializes in developing single molecule detection technology that enables lower costs and expanded use of high-qual

Genomic Health said recently that the German Federal Joint Committee (G-BA) has issued a positive reimbursement decision for its Oncotype DX Breast Recurrence Score test following a conclusion by the German Institute for Quality and Efficien

Recently, BD (Becton, Dickinson and Company) announced the appointment of Puneet Sarin as the global president of BD Bioscience, which took effect on the same day.

Recently, the 2019 Siemens Pharmaceutical Industry Summit was successfully held in Chengdu. During the conference, the world's leading biopharmaceutical industry supplier Sartorius Stedim Biotech and Siemens announced the global strategic co

Personalis announced recently that it has priced its initial public offering of around 7.9 million shares of common stock at $17 per share.

Amoy Diagnostics, Premia Holdings, and Loxo Oncology recently announced a partnership aimed at genetic screening of patients for a targeted cancer therapy.

Almac Diagnostic Services recently announced that it has received CE marking for a next-generation sequencing-based diagnostic assay that will be used to determine molecular eligibility for enrolling patients in a pivotal Phase 2 portion of

Thermo Fisher Scientific recently announced a number of new partnerships in conjunction with the annual American Society for Mass Spectrometry Conference in Atlanta.

Horizon Therapeutics has partnered with Invitae for its urea cycle disorder genetic (UCD) testing program, through which individuals who may have the rare genetic condition and their family members will receive testing at no charge.

Quanterix announced after the close of the market on Wednesday that it has inked an agreement to acquire privately held UmanDiagnostics for $22.5 million.